纖維肌痛治療市場規模、佔有率、成長及全球產業分析、區域洞察與預測（2026年至2034年）

纖維肌痛治療市場的成長要素

全球纖維肌痛治療市場預估2025年達到25.3億美元，2026年成長至26.6億美元，2034年達到40.2億美元，預測期間內複合年成長率（CAGR）為5.30%。 2025年，北美地區佔65.35%的市場佔有率，成為推動纖維肌痛治療市場成長的主要力量。纖維肌痛症是一種主要表現為全身疼痛、疲勞、睡眠障礙、情緒波動和記憶力減退的肌肉骨骼疾病。該市場的成長得益於疾病盛行率的上升、診斷技術的進步、研發活動的開展以及新療法的開發。

由於核准用於特定用途的藥物數量有限，仿單標示外用藥和學名藥在纖維肌痛的治療中被廣泛應用。然而，疼痛管理領域研發的活性化正推動著前景廣闊的新療法的研發。在研產品、新產品上市、醫療服務可及性的提高以及公眾對纖維肌痛認知的不斷增強，預計將在預測期內為市場擴張創造更多機會。

市場定義和範圍

纖維肌痛的治療包括使用藥物來控制與疾病相關的症狀，例如慢性疼痛、疲勞、睡眠障礙及其他相關症狀。整體治療方案包括已通過核准的藥物以及醫療專業人員可能根據患者需求使用的仿單標示外適應症用藥。

市場區隔按藥物類別進行，包括抗憂鬱症、抗癲癇藥、肌肉鬆弛劑和其他藥物（包括在研發線產品）。分銷管道包括醫院藥房、零售藥房和線上藥房。本報告也檢驗了區域市場細分、競爭趨勢、在研產品、監管因素以及新冠疫情的影響。

市場動態

成長要素

纖維肌痛盛行率的上升是推動市場成長的主要動力。據該報告顯示，美國約有500萬成年人患有纖維肌痛，其中女性患者佔很大比例。人們對纖維肌痛的認知不斷提高、診斷率上升、醫療保健支出增加以及政府和醫療保健機構的舉措，都促使人們越來越關注如何管理這種疾病。

強大的開發平臺和持續的研究預計也將為市場提供支撐。製藥公司正在探索創新療法，並評估現有藥物是否可用於治療纖維肌痛。臨床研究、新產品核准以及疼痛管理技術的進步，都為拓展治療選擇創造了機會。

趨勢

併購、產品研發和現有療法的拓展是關鍵的市場趨勢。各公司正在評估其他已獲批准藥物的適應症，並增加對纖維肌痛臨床試驗的投資。人們對創新療法的日益關注有望為患者提供更多治療選擇。

阻礙因素

仿單標示外學名藥的日益普及可能會阻礙獲準用於特定適應症的品牌藥的銷售成長。雖然歷史上獲準用於治療纖維肌痛的藥物數量有限，但專利到期後學名藥的競爭可能會進一步擠壓品牌藥的銷售。

新冠疫情的影響

新冠疫情對纖維肌痛治療市場造成了負面影響，原因在於疫情封鎖期間尋求治療的患者人數減少，以及醫療資源被轉移到新冠肺炎的治療和疫苗研發上。此外，藥品生產和供應鏈也受到干擾。預約延誤和就診人數減少進一步抑制了市場需求。疫情過後，隨著醫療服務、製藥業務、診斷和臨床研究的復甦，市場逐漸恢復正常。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇

第4章：主要考慮因素

• 按主要區域分類的纖維肌痛盛行率
• 主要行業趨勢
• 管道分析
• 監理展望
• 近期產業趨勢，例如併購
• 新冠疫情對市場的影響

第5章：2021-2034年全球纖維肌痛治療市場分析、洞察與預測

• 主要發現與總結
• 市場分析、洞察與預測：按藥物類別分類
  • 抗憂鬱症
  • 抗癲癇藥物
  • 肌肉鬆弛劑
  • 其他
• 市場分析、洞察與預測：按分銷管道分類
  • 醫院藥房
  • 零售藥房
  • 網路藥房
• 市場分析、洞察與預測：按國家/地區分類
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第6章：北美纖維肌痛治療市場分析、洞察與預測（2021-2034年）

• 國家
  • 美國
  • 加拿大

第7章：歐洲纖維肌痛治療市場分析、洞察與預測（2021-2034年）

• 國家
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 義大利
  • 斯堪地那維亞
  • 其他歐洲國家

第8章：亞太地區纖維肌痛治療市場分析、洞察與預測（2021-2034年）

• 國家
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家

第9章：拉丁美洲纖維肌痛治療市場分析、洞察與預測（2021-2034年）

• 國家
  • 巴西
  • 墨西哥
  • 其他拉丁美洲國家

第10章：中東和非洲纖維肌痛治療市場分析、洞察與預測（2021-2034年）

• 國家
  • GCC
  • 南非
  • 其他中東和非洲國家

第11章 競爭分析

• 主要行業趨勢
• 全球市佔率分析（2025 年）
• 競爭對手儀表板
• 主要公司比較分析
• 公司簡介
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Allegran
  • Tonix Pharmaceuticals
  • Aptinyx
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceuticals
  • Astella Pharma Inc
  • Other Prominent Players

第12章 戰略建議

Growth Factors of fibromyalgia treatment Market

The global fibromyalgia treatment market size was valued at USD 2.53 billion in 2025 and is projected to grow from USD 2.66 billion in 2026 to USD 4.02 billion by 2034, exhibiting a CAGR of 5.30% during the forecast period. North America dominated the fibromyalgia treatment market with a market share of 65.35% in 2025. Fibromyalgia is a musculoskeletal disorder primarily characterized by widespread pain, fatigue, sleep disturbances, mood changes, and memory problems. The market is supported by increasing disease prevalence, improving diagnosis, research and development activities, and the development of new treatment options.

The limited number of specifically approved medicines has resulted in substantial use of off-label and generic therapies for fibromyalgia management. However, increasing clinical research and development in pain management is supporting the development of potential new therapies. Pipeline products, product launches, improving healthcare access, and growing awareness of fibromyalgia are expected to create additional opportunities for market expansion during the forecast period.

Market Definition and Scope

Fibromyalgia treatment includes pharmaceutical therapies used to manage the symptoms associated with fibromyalgia, including chronic pain, fatigue, sleep disturbances, and related symptoms. The treatment landscape includes approved medicines as well as off-label therapies that may be used by healthcare professionals based on patient requirements.

The market is segmented by drug class into antidepressants, antiepileptic drugs, muscle relaxants, and others, including pipeline products. By distribution channel, the market includes hospital pharmacies, retail pharmacies, and online pharmacies. The report also examines regional markets, competitive developments, pipeline analysis, regulatory factors, and the impact of COVID-19.

Market Dynamics

Drivers

Increasing prevalence of fibromyalgia is a major factor supporting market growth. According to the supplied report, approximately five million adults in the U.S. suffer from fibromyalgia, with women representing a substantial proportion of diagnosed patients. Increasing awareness, diagnosis rates, healthcare expenditure, and government and medical organization initiatives are contributing to greater attention toward disease management.

Strong pipeline products and continued research are also expected to support the market. Pharmaceutical companies are investigating innovative therapies and evaluating existing medicines for potential fibromyalgia applications. Clinical research, new product authorizations, and improvements in pain-management technologies are creating opportunities for treatment expansion.

Trends

Mergers, acquisitions, product development, and expansion of existing therapies represent important market trends. Companies are increasingly evaluating established medicines for additional indications and investing in clinical trials for fibromyalgia. Growing interest in innovative therapies is expected to expand treatment choices for patients.

Restraints

The higher adoption of off-label and generic drugs can restrict revenue growth for specifically approved branded therapies. The market has historically had a limited number of medicines specifically approved for fibromyalgia, while generic competition following patent expirations can place additional pressure on branded product revenues.

Impact of COVID-19

The COVID-19 pandemic negatively affected the fibromyalgia treatment market as fewer patients sought treatment during lockdowns and healthcare resources were redirected toward COVID-19 medicines and vaccines. Pharmaceutical manufacturing and supply chains were also disrupted. Postponement of medical consultations and reduced treatment-seeking activity further affected demand. Recovery in healthcare services, pharmaceutical operations, diagnosis, and clinical research supported market normalization after the pandemic.

Segmentation Analysis

By drug class, antiepileptic drugs held a leading position in 2026, supported by strong adoption of established therapies such as Lyrica for fibromyalgia management. Antidepressants and muscle relaxants also represent important treatment categories, while pipeline products could influence the competitive structure.

By distribution channel, hospital pharmacies are expected to account for a 44.6% share in 2025. Retail pharmacies benefit from convenient access to medicines and the availability of over-the-counter products, while online pharmacies are gaining importance as digital healthcare distribution expands, particularly in developing markets.

Regional Insights

North America dominated the market, generating USD 1,253.5 million in revenue in 2025. High diagnosis rates, disease prevalence, availability of approved treatments, healthcare infrastructure, and continued pharmaceutical innovation are supporting regional growth.

Europe is anticipated to grow at a CAGR of 8.9% during the forecast period, supported by increasing prevalence, healthcare spending, limited treatment options, and potential product launches. Asia Pacific is expected to experience steady growth due to rising patient populations, healthcare expenditure, infrastructure development, and disease awareness. Japan's market is expected to reach USD 30.2 million by 2025, while China is projected to register a CAGR of 7.70%. Latin America and the Middle East & Africa are improving treatment availability through expanding public and private healthcare sectors.

Competitive Landscape

The market includes Pfizer, Inc., Eli Lilly and Company, Allergan, Tonix Pharmaceuticals, Aptinyx, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceuticals, and Astellas Pharma Inc. Companies are focusing on clinical development, product launches, mergers and acquisitions, manufacturing expansion, and pipeline development.

Recent developments include Tonix Pharmaceuticals' FDA review of TNX-102 SL for fibromyalgia in February 2025. Lilly announced major U.S. manufacturing investments, while Novartis announced plans for additional U.S. manufacturing facilities. These developments reflect continued investment in pharmaceutical production and innovation.

Report Coverage

The fibromyalgia treatment market report covers 2025 to 2034 and provides market size and value data for 2025, 2026, and 2034. It analyzes drug classes, distribution channels, market dynamics, COVID-19 impact, regional performance, pipeline products, regulatory factors, competitive strategies, and key industry developments across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Conclusion

The global fibromyalgia treatment market was valued at USD 2.53 billion in 2025 and is projected to reach USD 2.66 billion in 2026 and USD 4.02 billion by 2034, registering a CAGR of 5.30%. Increasing prevalence, improved diagnosis, rising healthcare awareness, pharmaceutical research, pipeline therapies, and potential product launches are expected to support market growth. North America remains the dominant regional market, while Europe and Asia Pacific are expected to provide important growth opportunities during the forecast period.

Unit Value (USD Million)

Segmentation Drug Class, Distribution Channel, and Region

By Drug Class

• Antidepressants
• Antiepileptic
• Muscle Relaxants
• Others (incl. Pipeline Products)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
  • By Drug Class
  • By Distribution Channel
  • By Country
• USA (By Drug Class)
• Canada (By Drug Class)
• Europe
  • By Drug Class
  • By Distribution Channel
  • By Country
• UK (By Drug Class)
• Germany (By Drug Class)
• France (By Drug Class)
• Italy (By Drug Class)
• Spain (By Drug Class)
• Scandinavia (By Drug Class)
• Rest of Europe (By Drug Class)
• Asia Pacific
  • By Drug Class
  • By Distribution Channel
  • By Country
• Japan (By Drug Class)
• China (By Drug Class)
• India (By Drug Class)
• Australia (By Drug Class)
• Southeast Asia (By Drug Class)
• Rest of Asia Pacific (By Drug Class)
• Latin America
  • By Drug Class
  • By Distribution Channel
  • By Country
• Brazil (By Drug Class)
• Mexico (By Drug Class)
• Rest of Latin America (By Drug Class)
• Middle East & Africa
  • By Drug Class
  • By Distribution Channel
  • By Country
• GCC (By Drug Class)
• South Africa (By Drug Class)
• Rest of MEA (By Drug Class)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Fibromyalgia by key Regions
• 4.2. Key Industry Trends
• 4.3. Pipeline Analysis
• 4.4. Regulatory Scenario
• 4.5. Recent Industry Developments Such as Mergers & Acquisitions
• 4.6. Impact of COVID-19 on the Market

5. Global Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Antidepressants
  • 5.2.2. Antiepileptic
  • 5.2.3. Muscle Relaxants
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Country
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Class
  • 6.2.1. Antidepressants
  • 6.2.2. Antiepileptic
  • 6.2.3. Muscle Relaxants
  • 6.2.4. Others
• 6.3. Market Analysis - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Drug Class
      • 6.4.1.1.1. Antidepressants
      • 6.4.1.1.2. Antiepileptic
      • 6.4.1.1.3. Muscle Relaxants
      • 6.4.1.1.4. Others
  • 6.4.2. Canada
    • 6.4.2.1. By Drug Class
      • 6.4.2.1.1. Antidepressants
      • 6.4.2.1.2. Antiepileptic
      • 6.4.2.1.3. Muscle Relaxants
      • 6.4.2.1.4. Others

7. Europe Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Class
  • 7.2.1. Antidepressants
  • 7.2.2. Antiepileptic
  • 7.2.3. Muscle Relaxants
  • 7.2.4. Others
• 7.3. Market Analysis - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis - By Country
  • 7.4.1. U.K.
    • 7.4.1.1. By Drug Class
      • 7.4.1.1.1. Antidepressants
      • 7.4.1.1.2. Antiepileptic
      • 7.4.1.1.3. Muscle Relaxants
      • 7.4.1.1.4. Others
  • 7.4.2. Germany
    • 7.4.2.1. By Drug Class
      • 7.4.2.1.1. Antidepressants
      • 7.4.2.1.2. Antiepileptic
      • 7.4.2.1.3. Muscle Relaxants
      • 7.4.2.1.4. Others
  • 7.4.3. France
    • 7.4.3.1. By Drug Class
      • 7.4.3.1.1. Antidepressants
      • 7.4.3.1.2. Antiepileptic
      • 7.4.3.1.3. Muscle Relaxants
      • 7.4.3.1.4. Others
  • 7.4.4. Spain
    • 7.4.4.1. By Drug Class
      • 7.4.4.1.1. Antidepressants
      • 7.4.4.1.2. Antiepileptic
      • 7.4.4.1.3. Muscle Relaxants
      • 7.4.4.1.4. Others
  • 7.4.5. Italy
    • 7.4.5.1. By Drug Class
      • 7.4.5.1.1. Antidepressants
      • 7.4.5.1.2. Antiepileptic
      • 7.4.5.1.3. Muscle Relaxants
      • 7.4.5.1.4. Others
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Drug Class
      • 7.4.6.1.1. Antidepressants
      • 7.4.6.1.2. Antiepileptic
      • 7.4.6.1.3. Muscle Relaxants
      • 7.4.6.1.4. Others
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Drug Class
      • 7.4.7.1.1. Antidepressants
      • 7.4.7.1.2. Antiepileptic
      • 7.4.7.1.3. Muscle Relaxants
      • 7.4.7.1.4. Others

8. Asia Pacific Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Class
  • 8.2.1. Antidepressants
  • 8.2.2. Antiepileptic
  • 8.2.3. Muscle Relaxants
  • 8.2.4. Others
• 8.3. Market Analysis - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis - By Country
  • 8.4.1. Japan
    • 8.4.1.1. By Drug Class
      • 8.4.1.1.1. Antidepressants
      • 8.4.1.1.2. Antiepileptic
      • 8.4.1.1.3. Muscle Relaxants
      • 8.4.1.1.4. Others
  • 8.4.2. China
    • 8.4.2.1. By Drug Class
      • 8.4.2.1.1. Antidepressants
      • 8.4.2.1.2. Antiepileptic
      • 8.4.2.1.3. Muscle Relaxants
      • 8.4.2.1.4. Others
  • 8.4.3. India
    • 8.4.3.1. By Drug Class
      • 8.4.3.1.1. Antidepressants
      • 8.4.3.1.2. Antiepileptic
      • 8.4.3.1.3. Muscle Relaxants
      • 8.4.3.1.4. Others
  • 8.4.4. Australia
    • 8.4.4.1. By Drug Class
      • 8.4.4.1.1. Antidepressants
      • 8.4.4.1.2. Antiepileptic
      • 8.4.4.1.3. Muscle Relaxants
      • 8.4.4.1.4. Others
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Drug Class
      • 8.4.5.1.1. Antidepressants
      • 8.4.5.1.2. Antiepileptic
      • 8.4.5.1.3. Muscle Relaxants
      • 8.4.5.1.4. Others
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Drug Class
      • 8.4.6.1.1. Antidepressants
      • 8.4.6.1.2. Antiepileptic
      • 8.4.6.1.3. Muscle Relaxants
      • 8.4.6.1.4. Others

9. Latin America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Class
  • 9.2.1. Antidepressants
  • 9.2.2. Antiepileptic
  • 9.2.3. Muscle Relaxants
  • 9.2.4. Others
• 9.3. Market Analysis - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis - By Country
  • 9.4.1. Brazil
    • 9.4.1.1. By Drug Class
      • 9.4.1.1.1. Antidepressants
      • 9.4.1.1.2. Antiepileptic
      • 9.4.1.1.3. Muscle Relaxants
      • 9.4.1.1.4. Others
  • 9.4.2. Mexico
    • 9.4.2.1. By Drug Class
      • 9.4.2.1.1. Antidepressants
      • 9.4.2.1.2. Antiepileptic
      • 9.4.2.1.3. Muscle Relaxants
      • 9.4.2.1.4. Others
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Drug Class
      • 9.4.3.1.1. Antidepressants
      • 9.4.3.1.2. Antiepileptic
      • 9.4.3.1.3. Muscle Relaxants
      • 9.4.3.1.4. Others

10. Middle East & Africa Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Class
  • 10.2.1. Antidepressants
  • 10.2.2. Antiepileptic
  • 10.2.3. Muscle Relaxants
  • 10.2.4. Others
• 10.3. Market Analysis - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis - By Country
  • 10.4.1. GCC
    • 10.4.1.1. By Drug Class
      • 10.4.1.1.1. Antidepressants
      • 10.4.1.1.2. Antiepileptic
      • 10.4.1.1.3. Muscle Relaxants
      • 10.4.1.1.4. Others
  • 10.4.2. South Africa
    • 10.4.2.1. By Drug Class
      • 10.4.2.1.1. Antidepressants
      • 10.4.2.1.2. Antiepileptic
      • 10.4.2.1.3. Muscle Relaxants
      • 10.4.2.1.4. Others
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Drug Class
      • 10.4.3.1.1. Antidepressants
      • 10.4.3.1.2. Antiepileptic
      • 10.4.3.1.3. Muscle Relaxants
      • 10.4.3.1.4. Others

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Pfizer, Inc.
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Eli Lilly and Company
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Allegran
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Tonix Pharmaceuticals
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Aptinyx
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Teva Pharmaceutical Industries Ltd.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Novartis AG
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Sun Pharmaceuticals
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Astella Pharma Inc
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Other Prominent Players
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

• Table 1: Global Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 2: Global Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 3: Global Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Region, 2021-2034
• Table 4: North America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 5: North America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 6: North America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, By Country, 2021-2034
• Table 7: Europe Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 8: Europe Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 9: Europe Fibromyalgia Treatment Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034
• Table 10: Asia Pacific Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 11: Asia Pacific Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 12: Asia Pacific Fibromyalgia Treatment Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034
• Table 13: Latin America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 14: Latin America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 15: Latin America Fibromyalgia Treatment Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034
• Table 16: Middle East & Africa Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Drug Class, 2021-2034
• Table 17: Middle East & Africa Fibromyalgia Treatment Market Revenue (USD Million) Forecast, by Distribution Channel, 2021-2034
• Table 18: Middle East & Africa Fibromyalgia Treatment Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

• Figure 1: Global Fibromyalgia Treatment Market Revenue Breakdown (USD Million, %) by Region, 2025 & 2034
• Figure 2: Global Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025 & 2034
• Figure 3: Global Fibromyalgia Treatment Market Forecast (USD Million), by Antidepressants, 2021-2034
• Figure 4: Global Fibromyalgia Treatment Market Forecast (USD Million), by Antiepileptic, 2021-2034
• Figure 5: Global Fibromyalgia Treatment Market Forecast (USD Million), by Muscle Relaxants, 2021-2034
• Figure 6: Global Fibromyalgia Treatment Market Forecast (USD Million), by Others, 2021-2034
• Figure 7: Global Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
• Figure 8: Global Fibromyalgia Treatment Market Forecast (USD Million), by Hospital Pharmacy, 2021-2034
• Figure 9: Global Fibromyalgia Treatment Market Forecast (USD Million), by Retail Pharmacy, 2021-2034
• Figure 10: Global Fibromyalgia Treatment Market Forecast (USD Million), by Online Pharmacy, 2021-2034
• Figure 11: Global Fibromyalgia Treatment Market Value (USD Million), by Region, 2025 & 2034
• Figure 12: North America Fibromyalgia Treatment Market Value (USD Million), by Drug Class, 2025 & 2034
• Figure 13: North America Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025
• Figure 14: North America Fibromyalgia Treatment Market Value (USD Million), by Distribution Channel, 2025 & 2034
• Figure 15: North America Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025
• Figure 16: North America Fibromyalgia Treatment Market Value (USD Million), By Country, 2025 & 2034
• Figure 17: North America Fibromyalgia Treatment Market Value Share (%), By Country, 2025
• Figure 18: Europe Fibromyalgia Treatment Market Value (USD Million), by Drug Class, 2025 & 2034
• Figure 19: Europe Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025
• Figure 20: Europe Fibromyalgia Treatment Market Value (USD Million), by Distribution Channel, 2025 & 2034
• Figure 21: Europe Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025
• Figure 22: Europe Fibromyalgia Treatment Market Value (USD Million), By Country/ Sub-region, 2025 & 2034
• Figure 23: Europe Fibromyalgia Treatment Market Value Share (%), By Country/ Sub-region, 2025
• Figure 24: Asia Pacific Fibromyalgia Treatment Market Value (USD Million), by Drug Class, 2025 & 2034
• Figure 25: Asia Pacific Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025
• Figure 26: Asia Pacific Fibromyalgia Treatment Market Value (USD Million), by Distribution Channel, 2025 & 2034
• Figure 27: Asia Pacific Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025
• Figure 28: Asia Pacific Fibromyalgia Treatment Market Value (USD Million), By Country/ Sub-region, 2025 & 2034
• Figure 29: Asia Pacific Fibromyalgia Treatment Market Value Share (%), By Country/ Sub-region, 2025
• Figure 30: Latin America Fibromyalgia Treatment Market Value (USD Million), by Drug Class, 2025 & 2034
• Figure 31: Latin America Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025
• Figure 32: Latin America Fibromyalgia Treatment Market Value (USD Million), by Distribution Channel, 2025 & 2034
• Figure 33: Latin America Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025
• Figure 34: Latin America Fibromyalgia Treatment Market Value (USD Million), By Country/ Sub-region, 2025 & 2034
• Figure 35: Latin America Fibromyalgia Treatment Market Value Share (%), By Country/ Sub-region, 2025
• Figure 36: Middle East & Africa Fibromyalgia Treatment Market Value (USD Million), by Drug Class, 2025 & 2034
• Figure 37: Middle East & Africa Fibromyalgia Treatment Market Value Share (%), by Drug Class, 2025
• Figure 38: Middle East & Africa Fibromyalgia Treatment Market Value (USD Million), by Distribution Channel, 2025 & 2034
• Figure 39: Middle East & Africa Fibromyalgia Treatment Market Value Share (%), by Distribution Channel, 2025
• Figure 40: Middle East & Africa Fibromyalgia Treatment Market Value (USD Million), By Country/ Sub-region, 2025 & 2034
• Figure 41: Middle East & Africa Fibromyalgia Treatment Market Value Share (%), By Country/ Sub-region, 2025
• Figure 42: Global Fibromyalgia Treatment Market Share (%), By Company, 2025